论文部分内容阅读
目的:研究同时性双侧乳腺癌临床病理特征及预后相关因素。方法:针对2008年1月至2019年3月北京大学第一医院乳腺疾病中心收治的同时性双侧乳腺癌临床病理特征、手术方式、预后等进行回顾性分析。结果:2008年1月至2019年3月，北京大学第一医院乳腺疾病中心共收治新发乳腺癌4 111例，同时性双侧乳腺癌57例，占全部乳腺癌患者1.4%。43例（75.4%）患者接受双侧乳腺全切手术。中位随访58个月，5年无病生存（DFS）为80.7%，5年总生存（OS）为84.1%。单因素分析发现第二癌N分期、第二癌人表皮生长因子受体2（HER2）表达与预后相关（n Z=5.866、4.231，均n P<0.05）。n 结论:双侧乳腺全切除是主要的外科治疗方式，综合治疗需兼顾双侧乳腺肿瘤的临床分期和预后分期评价。“,”Objective:To investigate the clinicopathologic features of synchronous bilateral breast cancer (SBBC) and prognostic factors.Methods:The clinicopathologic features of patients with SBBC treated in Peking University First Hospital from January 2008 to March 2019 were retrospectively analyzed.Results:Of all 4 111 patients diagnosed with breast cancer, 57(1.4%) cases were diagnosed with SBBC.Forty-three (75.4%) patients were treated with bilateral mastectomy. The median follow-up time was 58 months. The 5-year disease-free survival of SBBC was 80.7% and 5-year overall survival was 84.1%. The N stage and HER2 status of second primary breast cancer were associated with prognosis by univariated analysis (n Z=5.866 and 4.231, both n P<0.05).n Conclusion:Majority of patients with SBBC were treated with bilateral mastectomy. While therapeutic strategy of SBBC should take both tumor burden and biomarker status of bilateral breast cancer into consideration.